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HYPOGLYCEMIA IN MITOCHONDRIAL DISORDERS 
Allison Rachel Moats, BS, MA 
Advisory Professor: Myla Ashfaq, MS, CGC 
INTRODUCTION: The electron transport chain (ETC) in mitochondria functions to produce 
energy in the form of adenosine triphosphate (ATP). Defects in the mitochondrial or nuclear 
DNA that codes for components of the ETC lead to mitochondrial disorders (MTDs). MTDs are 
multi-system conditions affecting the heart, muscles, and especially brain. The endocrine system 
is commonly affected in MTDs, and diabetes and hyperglycemia are established secondary 
diagnoses. Rates of non-iatrogenic hypoglycemia have not been studied in individuals with 
MTDs. This study aims to investigate the frequency of hypoglycemia in patients with MTDs. 
METHODS: Individuals diagnosed with a ‘definite’ or ‘probable’ MTD according to the 
modified Walker criteria at The University of Texas, Mitochondrial Center of Excellence were 
included in this study. Exclusion criteria included diagnosis of diabetes or adrenal 
insufficiency or past or present use of hydrocortisone or prednisone. Patient charts were 
reviewed retrospectively for blood glucose values. Individuals with at least two values were 
recorded. Patients were classified as neonatal (≤28 days of life) or non-neonatal (>28 days of 
life) at the time of measurement. Data analysis included descriptive statistics, mixed-model 
regression, and two-sample tests of proportion. All data analysis was done using Stata® (v.13, 
College Station, TX). Statistical significance was assumed at p<0.05. 
RESULTS: Of the 116 patients included in this study, 22 (18.97%) experienced at least one 
episode of hypoglycemia. This is significantly higher (p<0.05) than the 6% non-diabetic, 
general population rate of hypoglycemia. Neonatal readings were also found to be 30mg/dL 
lower than non-neonatal readings, on average, a significant difference (p<0.05). 
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CONCLUSION: Patients with MTD are more likely to experience hypoglycemia compared to 
the general population with especially low blood glucose readings during the neonatal period. 
This demonstrates hypoglycemia may be contributing to the high rate of neurological symptoms 
reported in MTDs and supports that MTDs should be on the differential diagnosis in cases of 
hypoglycemia, especially during the neonatal period. Additional and earlier monitoring of blood 
glucose could reduce negative outcomes such as decreased cognitive outcome, developmental 
delays, seizures, or brain damage in patients with MTDs.  
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INTRODUCTION 
 
Mitochondria are organelles that engage in symbiotic relationships with eukaryotic cells: 
mitochondria provide energy in the form of adenosine triphosphate (ATP) for the cells in 
exchange for nutrients and proteins.1 Mitochondria are constructed from proteins coded for by 
mitochondrial DNA (mtDNA) and nuclear DNA (nDNA). The vast majority of ATP generated 
by mitochondria is created through the electron transport chain (ETC), a series of components 
that facilitate the exchange of electrons from chemical donors to chemical acceptors via 
reduction-oxidation reactions.2 When the ETC malfunctions, ATP yield decreases significantly 
leading to systemically low energy levels and multisystem malfunction. ETC dysfunction can be 
caused by errors in either mtDNA or nDNA due to both contributing to the structural 
composition of mitochondria. However, the majority of cases of ETC dysfunction are caused by 
mtDNA mutations.3 Individuals with ETC dysfunction are referred to clinically as having a 
mitochondrial disorder (MTD).1 
MTDs affect a multitude of organ systems due to systemically low levels of ATP. The 
heart, muscle, and brain are frequently affected tissues. Hallmark features of MTDs include 
depletion of mitochondrial material, ragged red fibers in the muscles, strokes, lactic acidosis, 
neuropathy, epilepsy, and encephalomyopathy.1 Prevalence of MTDs is known to be 1/4,3003, 
but because of the variable expressivity in these conditions, diagnosis can be complicated. 
Unlike other medical settings where genetic testing is able to give etiological information, this is 
not necessarily the case with MTDs. Only a small portion of the genetic etiologies of these 
conditions are understood at this time1, and in some cases, genetic yield is as low as 5%.4 
Genetic information is most useful when considered in combined with other MTD symptoms. 
The modified Walker criteria are a set of guidelines using a combination of clinical, 
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histological, enzymological, functional, and metabolic criteria in addition to genetic information 
to diagnose MTD as ‘definite’, ‘probable’, or ‘possible’.4 Clinical presentations can sometimes 
be separated into specific mitochondrial syndromes such as mitochondrial encephalomyopathy, 
lactic acidosis, and stroke-like episodes (MELAS); myoclonic epilepsy with ragged red fibers 
(MERRF); and neuropathy, ataxia, and retinitis pigmentosa (NARP). However, if the clinical 
presentation does not fit a specific mitochondrial syndrome, the patient may remain in an 
unspecified MTD category.1 Despite these differences in presentation, MTDs consistently cause 
symptoms in systems requiring high loads of ATP such as the nervous and endocrine systems.1 
The nervous system is the most frequently affected system, and forty-five percent of 
children with MTDs demonstrate neurological symptoms.1 Similarly, endocrine system-related 
symptoms (e.g., hypothyroidism, hypoparathyroidism, adrenal insufficiency, and diabetes) are 
commonly found in these individuals, specifically diabetes.1,5 Mitochondria and their ATP 
production in pancreatic islet β-cells are vital to the secretion of insulin in response to glucose 
stimulation.6 This balance is compromised in patients with MTD and leads to the 22.3% 
prevalence of diabetes and concomitant hyperglycemia in patients with MTDs.5 In addition to 
hyperglycemia, patients with MTDs and diabetes who manage their diabetes with insulin are 
known to experience iatrogenic hypoglycemia.7,8 
Unlike hyperglycemia, non-iatrogenic hypoglycemia, another sign of endocrine 
dysfunction, has not been well-documented in patients with MTDs. One case report described 
three unrelated individuals with MTDs who had hypoglycemia as their only presenting feature9. 
Otherwise, this correlation has not been studied. A recent study found the non-diabetic 
population rate of hypoglycemia to be 6%10, and learning whether the rate in the MTD 
population is significantly different or not is important due to the serious complications that can 
results from hypoglycemia. These complications can be divided into two categories: 1) 
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neurogenic, which affect the autonomic nervous system and range from sweating and shakiness 
and 2) neuroglycopenic, which affect the central nervous system, are much more severe, and can 
lead to severe cognitive impairment.11,12 Episodes of hypoglycemia that occur during periods of 
critical brain development are particularly damaging, and 25-50% of patients with neonatal 
hypoglycemia have developmental delay.12 If MTDs do increase rates of hypoglycemia, the 
related complications may, in turn, be contributing to the high rate of children with MTDs 
having neurological symptoms.1 This retrospective chart review aimed to determine how the 
frequency of hypoglycemia in a cohort of patients with MTDs without diabetes compared to the 
general population rate of 6.0%.10  
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METHODS 
 
This study followed all regulations established by the Institutional Review Board of the 
University of Texas at Houston Health Science Center (HSC-MS-09-0057). The University of 
Texas, Mitochondrial Center of Excellence (UTMCE) patient database was used for this 
retrospective chart review. 
Data Collection 
The electronic medical records (EMR) for patients seen at the UTMCE between 
November 1997 and December 2018 were reviewed for those who had genetic testing to 
determine the etiology of their MTD. They were then filtered for those who met ‘definite’ or 
‘probable’ MTD diagnosis based on the modified Walker criteria.4 The charts for patients 
meeting these criteria were systematically reviewed for measurements of serum glucose (SG) 
recorded in milligrams/deciliter (mg/dL) either from clinic-requested labs or inpatient testing at 
Children’s Memorial Hermann Hospital. Other information abstracted from the EMR included 
demographics (i.e., sex, ethnicity, place of residence); the patient’s mitochondrial syndrome if 
known; and whether the patient’s pathogenic variant is in the mtDNA, nDNA, or is unknown. 
Patients were separated into one of 12 categories based on their mitochondrial syndrome. 
Patients included in this study fell within the categories: combined oxidative phosphorylation 
deficiencies (COXPD), depletion syndrome, Kearns-Sayre syndrome, Leigh syndrome, 
MELAS, MERRF, MNGIE, NARP, an MTD plus another diagnosed condition (mito+), or an 
unspecified MTD. 
Exclusion Criteria 
Patients were excluded from the study if they had a medical condition known to 
influence SG either through its natural history or treatment, such as diabetes and adrenal 
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insufficiency, or if the patient had past or present use of steroids (i.e., hydrocortisone and 
prednisone). Patients with fewer than two SG measurements were also excluded. Any values 
greater than 500mg/dL were excluded due to questionable reliability of the glucometer above 
this cutoff. Any patient meeting one or more of the exclusion criteria was removed from the 
study. 
Data Classification 
SG measurements were categorized as neonatal or non-neonatal depending on if the 
patient was within the first 28 days of life or older than 28 days of life at the time of the 
measurement. For this study, we defined hypoglycemia in the neonatal period as SG less than or 
equal to 45mg/dL and hypoglycemia in the post-neonatal period as SG less than or equal to 
60mg/dL. A more stringent cutoff for neonatal hypoglycemia than the 55-60 mg/dL previously 
suggested12 was used as it is difficult to distinguish the difference between iatrogenic 
hypoglycemia and post-birth-transitional hypoglycemia. To facilitate the visualization of trends 
toward hypoglycemia, a category of low normal SG was defined as measurements up to 
10mg/dL higher than hypoglycemia in the respective age groups (i.e., neonatal and non-neonatal 
low normal SG ranged from 46-50mg/dL inclusive and 61-70mg/dL inclusive, respectively). 
Hyperglycemia in any age group was defined as SG greater than or equal to 200mg/dL. This is 
the cutoff for hyperglycemia following the administration of an oral glucose tolerance test7. This 
stringent value was used to denote measurements that are truly abnormally high. 
Data Analysis 
This cohort was evaluated using descriptive statistics. Categorical data were described 
using frequencies and percentages, and medians with interquartile ranges were used to describe 
continuous variables. Contingency tests, such as Chi2 and Fisher’s Exact, were used to compare 
categorical variables across groups. Additional statistical analysis between groups included a 
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random effects regression models, a mixed-effects regression analysis group, and two-sample 
tests of proportion. All data analysis was done using Stata® (v.13, College Station, TX). 
Statistical significance was assumed at p<0.05.  
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RESULTS 
 
At the time of data collection, the UTMCE patient database contained 799 patients. Two 
hundred sixty-three had undergone genetic testing, and of those, 168 met the criteria of having a 
‘definite’ or ‘probable’ MTD based on the modified Walker criteria.4 After excluding patients 
with a diagnosis of diabetes or adrenal insufficiency, past or current use of hydrocortisone or 
prednisone, or fewer than two SG measurements, 116 patients were included in the study. These 
patients had a combined total 1,787 SG measurements. 
Population Demographics and Serum Glucose Measurements 
In the cohort, 60/116 (51.72%) were female. The average age was 11.8 years (range=0 
days–65years). The majority of the patients reported Caucasian ethnicity (73/116, 62.93%). The 
most common mitochondrial syndromes were depletion syndrome (11.21%), Leigh syndrome 
(24.14%), and MELAS (10.34%). There were eight patients in the mito+ category. Nearly 82% 
of the patients had a pathogenic mutation found with most being in the mtDNA (51/116, 
42.97%). A total of 1,787 SG readings were collected with an average of 15.41 readings per 
patient. Of the 116 patients, nine (7.76%) had SG drawn during the neonatal period with 
99/1,787 (5.54%) total neonatal readings. All 116 patients collectively contributed to the 
1,688/1,787 non-neonatal readings (94.46%). Patient demographics can be found in Table 1, and 
SG measurement information can be found in Table 2. 
Statistical Analysis 
Of the total 1,787 SG readings collected, 51/1,787 (2.85%) were hypoglycemic. The 
majority of readings (95.86%) were either normal or low normal, and 23/1,787 (1.29%) were 
hyperglycemic (Table 2, Figure 1). The neonatal cohort was separated for individual analysis, 
and the remaining cohort (i.e., non-neonatal cohort) was also analyzed independently. The 
neonatal cohort had 17/99 (17.17%) hypoglycemic, 15/99 (15.15%) low normal, and 67/99   
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Patient Demographics  
 Category n (%) p-value p-value 
  Hypoglycemia Hyperglycemia 
Sex 0.210 0.487 
 Female 60 (51.72)   
Male 56 (48.28) 
Ethnicity 0.391 0.789 
 African American 5 (4.31)   
Asian 2 (1.72) 
Hispanic 14 (12.07) 
White 73 (62.93) 
Other 18 (15.52) 
Unknown 4 (3.45) 
Mitochondrial Condition 0.423 0.780 
 COXPD 3 (2.59)   
Depletion Syndrome 13 (11.21) 
Kearns-Sayre Syndrome 4 (3.45) 
Leigh Syndrome 28 (24.14) 
MELAS 12 (10.34) 
MERRF 2 (1.72) 
MNGIE 1 (0.86) 
NARP 2 (1.72) 
Mitochondrial Disorder+ 8 (6.90) 
Unspecified  43 (37.07) 
Pathogenic Mutation 0.356 0.637 
 mitoDNA 51 (43.97)   
nDNA 21 (18.10) 
Unknown 44 (37.93) 
  Total n=116   
*Mitochondrial Disorder+ = meeting the Walker Criteria diagnosis of mitochondrial disorder + 
a second diagnosis including: dopa dystonia (2), Friedreich’s ataxia (1), malignant hyperthermia 
(1), multiple sclerosis (1), partial ornithine carbamoyltransferase (1), spondyloepimetaphyseal 
dwarfism (1), and a 651kb interstitial deletion on chromosome 22 (1). 
Table 1: Patient Demographics 
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Summary of Number of Blood Glucose Measurements    
 Category n (%) Range Recurrence (%) Frequency (%) p-value 
Numbers Per Patient    
 Mean 15.41 
2–99 
   
Median 8.5 
Whole Cohort Totals    
 
Hypoglycemia 51 (2.85) 1–11 
 
 
 
1–6 
33.36 
 
 
 
41.67 
1.1–40 
 
 
 
1.1–50 
 
Low Normal 97 (5.43) 
Normal 1,616 (90.43) 
Hyperglycemia 23 (1.29) 
  Total n=1,787    
Totals by Age 
†Neonatal Cohort  
(n=9) 
Hypoglycemia 17 (17.17) 2–11 
 
 
 
 
100 
 
 
 
 
8.33–19.05 
 
 
 
 
p<0.05* 
p<0.05** 
 
 
 
Low Normal 15 (15.15) 
Normal 67 (67.68) 
Hyperglycemia 0 (0.00) 
  Total n=99 (5.54)     
Non-Neonatal Cohort 
(n=107) 
Hypoglycemia 34 (2.01) 1–9 
 
 
 
1–6 
17.76 
 
 
 
41.67 
1.1–40 
 
 
 
1.1–50 
 
 
 
 
 
Low Normal 82 (4.86) 
Normal 1,549 (91.77) 
Hyperglycemia 23 (1.36) 
  Total n=1,688 (94.46)     
*Between rate of neonatal hypoglycemia and rate of non-neonatal hypoglycemia in this study by Chi2 and mixed-effect regression model 
**Between rate of neonatal hypoglycemia and rate of non-diabetic hypoglycemia10 
†Neonatal = ≤28 days of life 
Table 2: Summary of Number of Blood Glucose Measurements  
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Figure 1: Glucose Values for Each Study Subject  
  
(67.68%) normal measurements (Table 2, Figure 2). There was no neonatal hyperglycemia. The 
non-neonatal cohort had 34/1,688 (2.01%) hypoglycemic, 82/1,688 (4.86%) low normal, 
1,549/1,688 (91.77%) normal, and 23/1,688 (1.36%) hyperglycemic SG measurements (Table 2, 
Figure 2). 
The median SGs were calculated per patient, and when these values were averaged 
across the whole patient cohort, the mean was 90.32mg/dL (range=66–149.5mg/dL) (Table 3). 
The minimum and maximum values for each patient were also averaged across the cohort and 
can be found in Table 3. Similar calculations were done for the neonatal and non-neonatal 
cohorts and can also be found in Table 3. 
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Summary of Blood Glucose Values (mg/dL)  
 Category n Range Total Readings 
Averages  
Whole Cohort 
(n=116) 
Median 90.32 66–149.5 
1,787 Low 70.64 14–108 
High 135.36 67–433 
Averages by Age     
†Neonatal Cohort  
(n=9) 
Median 79.33 68–86 
99 Low 29.00 14–43 
High 204.00 156–257 
Non-Neonatal Cohort 
(n=107) 
Median 90.62 66–149.5 
1,688 Low 71.74 29–108 
High 133.54 67–433 
†Neonatal = ≤28 days of life 
Table 3: Summary of Blood Glucose Values 
 
 
 
Figure 2: Low Normal and Hypoglycemic Glucose Values (n=48) 
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Of the 116 patients, 22/116 (18.97%) experienced at least one SG reading of 
hypoglycemia as their lowest reading (Table 4.1). Just over 13% (3/22) of these readings were 
neonatal (Table 4.2). An additional 26/116 patients (22.41%) experienced low normal SG as 
their lowest reading (Table 4.1), three of which were neonatal (11.54%) (Table 4.2). The 
remaining 68/116 patients (58.62%) had a normal SG as their lowest value (Table 4.1). In terms 
of their highest readings, 12/116 patients (10.34%) experienced hyperglycemia (Table 4.1), 
none of which were neonatal. The vast majority of patients had a normal value as their highest 
SG (103/116, 88.79%), and only one patient had a low normal reading as their highest SG 
(1/116, 0.86%) (Table 4.1). 
Of the 22 patients with hypoglycemic measurements, one third experienced recurrent 
hypoglycemia defined as more than one hypoglycemic reading (Table 2). 100% of neonatal 
patients experienced repeat hypoglycemia (Table 2). Nearly half of patients with hyperglycemia 
experience recurrence of these (Table 2). By number of readings, there was a statistically 
significant increase in the rate of hypoglycemia in neonatal patients compared to non-neonatal 
patients (17.17% versus 2.01%; p<0.05) (Table 2). 
Using Chi2 analyses, there were no statistically significant differences in the likelihood 
of having hypoglycemia depending on the patient’s sex (p=0.210), ethnicity (p=0.391), specific 
diagnosis (p=0.423), or the location of their pathogenic mutation (p=0.356) (Table 1). There 
were also no statistically significant differences with hyperglycemia and any of these categories 
(sex p=0.487; ethnicity p=0.789; specific diagnosis p=0.780; location of pathogenic mutation 
p=0.637) (Table 1). When assessing for time trends using a random effects regression model, 
there was no statistically significant increases or decreases in SG readings for every day of life 
gained (p=0.1403; 95% CI [-0.028]–0.199). Mixed-effects regression analysis showed a 
statistically significant difference in the SG readings based on whether the individual was a  
13 
 
Table 4.1 
Cross Tabulation of Blood Glucose Minimums and Maximums by Individual (Total) 
M
in
im
u
m
 R
ea
d
in
g
 
 Maximum Reading 
Totals (%) 
 
Hypoglycemia Low Normal Normal Hyperglycemia 
Hypoglycemia 0 0 18 4 22 (18.97)* 
Low Normal 0 1 20 5 26 (22.41) 
Normal 0 0 65 3 68 (58.62) 
Hyperglycemia 0 0 0 0 0 
Totals (%) 0 1 (0.86) 103 (88.79) 12 (10.34) 116 
 
 
Table 4.2 
Cross Tabulation of Blood Glucose Minimums and Maximums by Individual (†Neonatal) 
M
in
im
u
m
 R
ea
d
in
g
 
 Maximum Reading 
Totals (%) 
 
Hypoglycemia Low Normal Normal Hyperglycemia 
Hypoglycemia 0 0 3 0 3/116 (2.59) 
Low Normal 0 0 3 0 3/116 (2.59) 
Normal 0 0 3 0 3/116 (2.59) 
Hyperglycemia 0 0 0 0 0 
Totals (%) 0 0 (0) 9/116 (7.76) 0 (0) 9/116 
*Denotes a statistically significant difference from general population values in non-diabetic patients10 
†Neonatal = ≤28 days of life 
Tables 4.1 & 4.2: Cross Tabulation of Blood Glucose Minimums and Maximums by Individual (Total & Neonatal) 
Non-neonatal hypoglycemia = ≤60mg/dL, low normal = 61-70mg/dL, normal = 71-199mg/dL, and hyperglycemia = ≥200mg/dL. Neonatal 
hypoglycemia = ≤45mg/dL, low normal = 46-50mg/dL, normal = 51-199mg/dL, and hyperglycemia = ≥200mg/dL
14 
 
neonate (p<0.05, 95% CI [-36.802]–[-23.715]) showing that on average, neonatal readings are 
30mg/dL lower than non-neonatal readings. In this model, there was no difference in SG 
readings for each year of life gained (p=0.222, 95% CI [-0.247]–0.057) or between females and 
males (p=0.834, 95% CI [-3.755]–4.654). A two-sample test of proportion showed a statistically 
significant increase in our cohort’s frequency of hypoglycemia (22/116=18.97%) compared to 
the previously found population rate of hypoglycemia in patients without diabetes of 6.0%10 
(p<0.05, 95% CI 0.43–0.186) (Table 2). A two-sample test of proportion also showed no 
statistically significant difference in our cohort’s frequency of hypoglycemia compared to the 
previously found population rate of hypoglycemia in patients with diabetes of 16.8%10 
(p=0.8615, 95% CI [-0.065]–0.078).  
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DISCUSSION 
 
This study is the first to investigate the frequency of hypoglycemia in patients with 
MTDs diagnosed by the modified Walker criteria.4 The vast majority of SG measurements 
(95.86%) were either normal or low normal demonstrating the cohort experiences normal SG 
the majority of the time. This was reiterated by the cohort-wide and non-neonatal averages of 
mean, minimum, and maximum all being between 60mg/dL and 200mg/dL and, thus, higher 
than either the cutoff for hypoglycemia or lower than the cutoff for hyperglycemia. While the 
minimum and maximum for the neonatal cohort are both lower and higher than the normal 
cutoffs, respectively, these are likely a reflection of a smaller sample size and possibly unknown 
neonatal risk factors such as gestational age, maternal diabetes, and yet undiagnosed diabetes.12 
Despite the majority of readings being normal, 18.97% of the cohort experienced 
hypoglycemia (Table 4.1). This rate was similar to the 16.8% rate previously reported in 
diabetic populations10 but is statistically higher than the 6.0% frequency found in a general, non-
diabetic population.10 Recurrence of hypoglycemia was 33.36% in the full cohort and 100% in 
neonates. The frequency of recurrence of hyperglycemia was unexpected considering the 
population is void of individuals with diabetes, and rates of hyperglycemia are predicted to be 
low in unaffected populations as these readings may be used to diagnose diabetes.7 However, as 
this study is a retrospective chart review, the patients may be diagnosed with diabetes 
eventually. Regardless, increased rates of both hypoglycemia and hyperglycemia demonstrate 
endocrine malfunction.1 
 When considering individual readings, the frequency of hypoglycemia in neonates is 
significantly increased compared to that in non-neonatal frequency. Neonatal SG is known to be 
lower than that of older children and adults12, and this was reflected in this study by using a 
lower threshold for hypoglycemia in neonates. Regardless, a 30mg/dL decrease still exceeds the 
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established difference in cutoffs and indicates neonates with MTD may be predisposed to 
abnormally low hypoglycemia. However, other unknown neonatal risk factors may have played 
a role in these levels.12 
Recently, a study looking at a group of patients with Prader-Willi syndrome found 
12.6% frequency of hypoglycemia in the neonatal population.13 Prader-Willi syndrome is also 
commonly associated with endocrine dysfunction, and Harrington et al. suggested neonatal 
hypoglycemia may play a role in the diminished neurological abilities of these patients.13 Our 
population of non-diabetic patients with MTDs was three times more likely to experience 
hypoglycemia than the non-diabetic general population.10 Additionally, neonates were 
significantly more likely to experience SG readings 30mg/dL lower than their non-neonatal 
counterparts. These findings supports the notion that endocrine malfunction may be one of the 
first symptoms of MTD and may severely influence SG levels in neonates. Children with MTDs 
may experience diminished neurocognitive abilities due to hypoglycemia in early life or later 
undiagnosed hypoglycemia.1,13 
Study Limitations 
 There are several inherent limitations to a retrospective chart review. Information 
regarding whether the SG values were fasting or reactive was not available. Similarly, the nature 
of the EMR made it difficult to ascertain the full course of treatment for the episodes of 
hypoglycemia, making it impossible to determine if these occurrences would qualify as true, 
clinical hypoglycemic episodes or if they are artifact hypoglycemia. Information regarding 
when the patient may have started treatment for the symptoms of their disease was also not 
available, and we are unable to say whether this influenced their SG readings. Because this 
study is retrospective, patient outcomes, such as whether or not the patients develop diabetes, 
are not known. Lastly, birth information, such as weight or gestational age, for neonatal patients 
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was not collected. Without this information, the possibility of neonatal hypoglycemia being due 
to other neonatal risk factors12 cannot be eliminated.  
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CONCLUSION 
 
Based on the finding of 18.97% hypoglycemia in this non-diabetic, MTD population, 
glucose monitoring for low SG values should become standard of care. These data also support 
that endocrine malfunction may be one of the first symptoms of MTDs. Forty-five percent of 
children with MTDs demonstrate neurological symptoms1, and this study demonstrates that it is 
reasonable to consider at least a portion of those childrens’ symptoms may be due to aberrant 
glucose values, particularly during critical brain development. MTDs should be on the 
differential diagnosis in cases of hypoglycemia, particularly neonatal hypoglycemia. Thornton 
et al. previously published recommendation for the monitoring of neonates with recurrent 
episodes of hypoglycemia12, and this study demonstrates that analysis for MTD by modified 
Walker criteria may be warranted in the presence of repeat neonatal hypoglycemia. 
Additionally, very low hypoglycemia may be another indication warranting MTD analysis, 
particularly if in the presence of repeat hypoglycemia. Identifying patients with MTD as early as 
possible to avoid the serious neurological complications that can result from uncontrolled 
glucose such as decreased cognitive abilities, developmental delay, seizures, or death is 
important for best health outcomes. 11,12 Future longitudinal studies following patients from 
birth with information regarding whether the SG readings are fasting or reactive would help 
establish patterns throughout development and whether hypoglycemia leads to specific 
complications in the future  
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